Bio News
Prestige Biologics reported a net loss of 51.2 billion won for fiscal 2026.
The auditor determined that there was material uncertainty about the company’s ability to continue as a going concern because current liabilities exceeded current assets by 107.6 billion won.
Prestige Biologics is pursuing a 5-to-1 reverse stock split through a bonus capital reduction.
BIOBOOK TEAM
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
